{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-115300","form_type":"8-K","ticker":"IOVA","cik":"0001425205","company_name":"IOVANCE BIOTHERAPEUTICS, INC.","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.419166+00:00","generated_at":"2026-05-30T03:25:50.716289+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Iovance Q3 product revenue $58.6M; net loss narrows to $0.28/shr; FY24 guidance reaffirmed","bullets":["Q3 2024 product revenue $58.6M ($42.1M Amtagvi, $16.5M Proleukin); net loss $83.5M ($0.28/shr) vs $113.8M ($0.46/shr) YoY.","Reaffirms FY24 total product revenue guidance of $160-$165M and FY25 guidance of $450-$475M.","146 patients infused with Amtagvi since Apr 2024 launch; 82 infusions in Q3; 56 ATCs onboarded, targeting 70 by year-end.","Regulatory submissions accepted in EU, UK, Canada; potential approvals in 1H2025 (UK) and 2H2025 (EU, Canada).","Enrollment accelerating in IOV-LUN-202 Phase 2 NSCLC trial; potential accelerated U.S. approval for lifileucel in NSCLC expected in 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-115300","json":"https://secwatch.observer/filing/0001104659-24-115300.json","markdown":"https://secwatch.observer/filing/0001104659-24-115300.md","text":"https://secwatch.observer/filing/0001104659-24-115300.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1425205/000110465924115300/0001104659-24-115300-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1425205/000110465924115300/tm2427769d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T03:25:50.716289+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}